P218   Click here for help

GtoPdb Ligand ID: 9740

Synonyms: MMV000147
PDB Ligand Antimalarial Ligand
Compound class: Synthetic organic
Comment: The antifolate compound P218 is a potent and selective inhibitor of P. falciparum bifunctional dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) and was designed to overcome the emergence of parasite resistance to this class of antimalarial compound [7].

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 133.58
Molecular weight 360.18
XLogP 1.72
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCc1nc(N)nc(c1OCCCOc1ccccc1CCC(=O)O)N
Isomeric SMILES CCc1nc(N)nc(c1OCCCOc1ccccc1CCC(=O)O)N
InChI InChI=1S/C18H24N4O4/c1-2-13-16(17(19)22-18(20)21-13)26-11-5-10-25-14-7-4-3-6-12(14)8-9-15(23)24/h3-4,6-7H,2,5,8-11H2,1H3,(H,23,24)(H4,19,20,21,22)
InChI Key VDGXZSSDCDPCRF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
P218 has entered Phase 1 clinical trial for malaria. A first-in-human study to confirm the safety, tolerability and pharmacokinetics of P218 in healthy adult subjects (NCT02885506) has been completed and results published [2,6]. A Phase 1b trial, to evaluate the safety, tolerability and chemoprotective activity of P218 in a P. falciparum sporozoite infection model has also been completed and results posted with ClinicalTrials.gov (NCT03707041) [1].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
P218 is a selective inhibitor of P. falciparum bifunctional dihydrofolate reductase-thymidylate synthase (PfDHFR-TS), binding to the active site of DHFR differently than to the human enzyme [7]. In contrast to pyrimethamine, P218 employs a a slow-on/slow-off tight-binding mode as well as binding both wild-type and pyrimethamine-resistant quadruple mutant PfDHFR, which could prolong the the target residence time [7].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03707041 Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model Phase 1 Interventional Medicines for Malaria Venture 1
NCT02885506 A FIH Study to Investigate the Safety, Tolerability and PK of P218 Phase 1 Interventional Medicines for Malaria Venture Favourable safety, tolerability and pharmacokinetics displayed. The short half-life will reqiure a long‐acting formulation. 2,6
Pharmacokinetics Click here for help
Elimination
P218 has a half-life ranging from 3.1 to 6.7 hours (doses of 10 and 30 mg) increasing to 19.6 hours with higher doses (up to 1000 mg) [2].